Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer.
Cantwell
B M
BM
Hennessy
C
C
Sawan
A
A
Dawes
P J
PJ
Millward
M
M
Lennard
T W
TW
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D004317:Doxorubicin / Q000008:administration & dosage; D066246:ErbB Receptors / Q000235:genetics* / Q000502:physiology; D005260:Female; D015870:Gene Expression / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D015080:Mesna / Q000008:administration & dosage; D009154:Mutation; D011379:Prognosis; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin; D066246:ErbB Receptors; D015080:Mesna; D007069:Ifosfamide